Date: 2026-02-22 Quarter: Q4 FY25 (Dec-25) Market cap: ~$1.5B | Run-rate P/S: ~1.1x | Revenue growth: 20% YoY, -4.3% QoQ Scout brief: briefs/PGY_earnings-review_2026-02-21/ Atlas baseline: Read. Broadly agree. Adding WSM-specific trajectory and leading indicator analysis.
PGY does not meet my investment criteria. Revenue decelerated sharply (36% → 20% YoY), Q4 showed a sequential decline (-4.3% QoQ), and 2026 guidance midpoint implies ~15% growth. Two of the three conditions for a sell signal are met. This is a value/turnaround setup in a cyclical credit business — not my game. The stock is already down ~47% since earnings, so the damage is done. Not interested. Watchlist only if credit cycle turns and growth re-accelerates above 30%.
| Q1_23 | Q2_23 | Q3_23 | Q4_23 | Q1_24 | Q2_24 | Q3_24 | Q4_24 | Q1_25 | Q2_25 | Q3_25 | Q4_25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue ($m) [Non-GAAP includes other income] | 186.6 | 195.6 | 211.8 | 218.0 | 245.0 | 250.0 | 257.0 | 279.4 | 290.0 | 326.0 | 350.0 | 335.0 |
| QoQ % | — | 4.8% | 8.3% | 2.9% | 12.4% | 2.0% | 2.8% | 8.7% | 3.8% | 12.4% | 7.4% | -4.3% |
| YoY % | — | — | — | — | 31.3% | 27.8% | 21.3% | 28.2% | 18.4% | 30.4% | 36.2% | 20.1% |
| Adj EBITDA ($m) [Non-GAAP] | — | — | — | — | — | — | — | — | 80 | 86 | 107 | 98 |
| GAAP Net Income ($m) | — | — | — | — | — | — | — | -237.9* | 8.0 | 17.0 | 23.0 | 34.0 |
| FRLPC ($m) [Non-GAAP] | — | — | — | — | — | — | — | — | — | — | — | 131 |
| Network Volume ($B) | — | — | — | — | — | — | — | — | — | — | — | 2.7 |
*Q4'24 net loss was a one-time impairment/writedown — not operational.
YoY trajectory: 31.3% → 27.8% → 21.3% → 28.2% → 18.4% → 30.4% → 36.2% → 20.1% → Peak Q3 at 36%, then snap down to 20% in Q4. 2026 guide midpoint: ~15%. This is a decelerating trajectory with further deceleration baked into guidance.
QoQ: Q4 was literally negative (-4.3%). Yes, Q4 is seasonally weak for consumer lending — but comparing same-quarter QoQ: Q4'24 was +8.7% QoQ. Q4'25 at -4.3% is a massive miss vs historical seasonal pattern.
The one area where PGY delivered was profitability. Four consecutive quarters of GAAP profitability in FY25. $81M GAAP net income for the year. Adj EBITDA margin of 29% in Q4. GAAP EPS $0.36 in Q4, $0.93 for FY25.
This matters. A year ago the stock was losing hundreds of millions GAAP (Q4'24 -$237.9M writedown, chronic losses before that). The profitability inflection is real and structural. But I buy growth, not profitability inflections. Revenue growth is the primary screen.
| Metric | Q4'25 | FY'25 | Assessment |
|---|---|---|---|
| Revenue YoY | 20% | 26% | Below my 30% threshold |
| FRLPC margin on rev [Non-GAAP] | ~39% | ~39% | Well below 60% SaaS standard |
| Adj EBITDA margin [Non-GAAP] | 29% | 28.5% | Decent for a fintech |
| GAAP net margin | 10.1% | 6.2% | Positive — that's progress |
| Guidance beat track record | 4/4 quarters beat/in-range on EBITDA | Positive signal |
CEO Gal Krubiner: "We are becoming a better Pagaya, not just a bigger one."
Translation: we slowed growth deliberately. The explicit claim is that management cut 100 − 150Min * *annualized * *volume( 25-37M/quarter) from higher-risk credit tiers in late Q4 due to "persistent consumer uncertainty and trends." They frame this as proactive credit discipline, not demand deterioration.
The argument for the bull case:
The problem: even accepting the ex-SFR framing, 2026 revenue guidance midpoint is $1.49B vs FY25 $1.30B = +15% YoY. Management is not guiding for re-acceleration. They are guiding for further deceleration. If they were confident the Q4 dip was transient, the 2026 guide would show it.
→ The numbers and the guidance confirm deceleration. The narrative does not change the trajectory.
Network volume vs Revenue: FY25 network volume +9% YoY vs revenue +26%. Revenue growing faster than volume = improving monetization (FRLPC margin expansion). This is actually a good sign for unit economics. But Q4 network volume missed guidance ($2.7B vs $2.75-2.95B guide). Volume is the leading indicator for PGY, and it missed.
2026 volume guidance: 11.25B−13.0B vs $10.5B FY25 = +7% to +24% YoY. Wide range reflects genuine uncertainty. Midpoint $12.1B = +15%.
FRLPC margin: 4.8% in Q4 ($131M / $2.7B network volume). 2026 guide 4-5%. Flat to slightly compressing. No expansion catalyst visible.
New partners: Achieve, GLS, BNPL provider onboarded in 2025 with "long-term fee and volume commitments." These should add incremental volume in 2026. Management says this underpins confidence in the volume guidance. Not yet quantified.
→ Leading indicators are weak to neutral. No divergence that signals hidden acceleration. Volume missed, FRLPC margin stable, new partners not yet visible in numbers.
Four quarters of beats in FY25 — consistently at the upper end of guidance on EBITDA, beat significantly on GAAP net income. Revenue in-range all year. This is a management that under-promises and over-delivers on profitability. Credit where it's due.
| Period | Rev vs Guide | EBITDA vs Guide | Net Income vs Guide |
|---|---|---|---|
| Q1'25 | Beat | Beat | Beat |
| Q2'25 | Beat | Beat | Beat |
| Q3'25 | Beat (upper) | Beat (above range) | N/A |
| Q4'25 | In-range | Beat (upper) | Beat significantly ($34M vs $10-20M guide) |
The Q4 GAAP net income beat of $34M vs $10-20M guide is notable. If 2026 guides $100-150M GAAP net income and they beat at the same rate, we're looking at $130-180M — at current $1.5B market cap that's 8-11x P/E. That's genuinely cheap.
But I buy revenue growth acceleration. Not earnings beats on decelerating growth.
| Metric | Value | Notes |
|---|---|---|
| Market cap | ~$1.5B | Post -47% washout |
| Run-rate revenue (Q4 × 4) | $1.34B | [Non-GAAP — includes other income] |
| Run-rate P/S | 1.1x | Extremely cheap |
| Run-rate net income (Q4 × 4) | $136M | [GAAP] |
| Run-rate P/E | 11x | [GAAP] |
| 2026 fwd net income (guide mid) | $125M | [GAAP] |
| 2026 fwd P/E | 12x | [GAAP] |
| Adj EBITDA run-rate (Q4 × 4) | $392M | [Non-GAAP] |
| Run-rate EV/EBITDA | ~3.8x | [Non-GAAP] |
By any traditional valuation metric this is cheap. Dirt cheap. The market is pricing in credit cycle deterioration, ABS impairments, or structural growth decline. If none of those materialise, the re-rating potential is substantial.
This is not a trade I will make. PGY is fundamentally a cyclical financial company dressed in AI language. Revenue growth is decelerating. Gross margins (FRLPC proxy ~39%) are too low. The ABS securitization model creates opacity I can't see through. And I have 11 higher-conviction positions. Why would I reach for a value play in a credit cycle?
→ The valuation case is real but it's not my game. Watchlist.
Atlas correctly called Gate FAIL on revenue growth and gross margins. The six-factor scoring is sound. I broadly agree with the anti-thesis framing.
Where I add nuance:
Where I land differently: Atlas gives Conviction 2 with "speculative value" framing. That's fair for a generalist. For me, sub-30% revenue growth = not investable regardless of valuation. Full stop.
| Prior | Updated | |
|---|---|---|
| Growth trajectory | No prior view — first analysis | Decelerating. Peak 36% (Q3'25) → 20% (Q4'25) → guided ~15% (FY26). Structural slowdown, not transient. |
| Profitability | No prior view | Genuine inflection. 4 consecutive GAAP profitable quarters. Management has proven they can deliver on this. |
| Credit risk | No prior view | Management proactively tightened. $100-150M impairment buffer in 2026 guide. Not a red flag if they were proactive — but it's a yellow flag. |
| Valuation | No prior view | Dirt cheap at 11x run-rate GAAP P/E. Value case is real. Not my framework. |
| Management | No prior view | CEO prioritising quality over growth ("better Pagaya, not bigger"). Positive for stability. Negative for growth re-acceleration thesis. |
Not interested at current trajectory.
Re-engage criteria:
If all four hit, PGY at 1x revenue and 10x earnings would be extremely interesting. Until then, pass.
Long: CRDO, NBIS, MU, HNGE, RBRK, APP, AXON, IREN, ALAB, FIGR, RDDT. No position in PGY. -wsm